Development of intracrine androgen deprivation therapy for prostate cancer
Project/Area Number |
21592035
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Niigata University |
Principal Investigator |
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 前立腺癌 / アンドロゲン抑制療法 / アンドロゲン代謝 / 細胞内分泌学 / 細胞内アンドロゲン代謝 / ジヒドロテストステロン / デヒドロエピアンドロステロン / HSD17B6 / 3αアンドロスタンディオール / アンドロゲン受容体 / 下垂体-副腎内分泌軸 |
Research Abstract |
The androgen milieu in men with high Gleason score prostate cancer is probably less affected by conventional androgen deprivation therapy than that in men with low score cancer, which was suggested to be associated with adrenal androgen levels. In patients treated with androgen deprivation therapy the pituitary-adrenal axis mediated by adrenocorticotropic hormone、in addition dehydroepiandrosterone-dihydrotestosterone axis has a central role in the regulation of androgen synthesis.
|
Report
(4 results)
Research Products
(34 results)